UNLABELLED: Breast and endometrial cancers are the most common invasive malignancies in women, with more than 217,000 new diagnoses per year in the United States. These cancers are often classified into 2 subtypes based on the expression of the classical estrogen receptor. In this study, we describe a new structural class of neutral tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivatives for potential use in breast and endometrial cancer imaging. METHODS: The 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative was synthesized via the Sonogashira cross-coupling reaction and radiolabeled via the tricarbonyl approach. Radiochemical purity was assessed by high-performance liquid chromatography. Cell-binding studies were performed with human breast adenocarcinoma MCF-7 cells. The in vivo biodistribution of the 99mTc(I) derivative was evaluated in virgin female C57BL/6 mice in defined phases of the estrous cycle. Biodistribution and SPECT/CT studies were performed with mice bearing MCF-7 and primary human endometrial tumors. RESULTS: Radiochemical analysis demonstrated that the postpurification purity of the 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative was > or =95%, with a specific activity of 99mTc of 47.5 TBq/mmol. Cell-binding studies yielded a dissociation constant (mean +/- SEM) of 11 +/- 1.5 nM. In vivo studies revealed that receptor-mediated uptake was present in all phases of the estrous cycle in reproductive organs and mammary glands but was highest during the diestrous phase of the estrous cycle. Despite high nonspecific uptake in the liver, significant receptor-mediated uptake was observed in target tissues and estrogen receptor-expressing tumors (0.67% for MCF-7 tumors and 0.77% for endometrial tumors). Tumor uptake was reduced by approximately 50% on coinjection with 17beta-estradiol. CONCLUSION: We have characterized a novel neutral tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for potential use in breast and endometrial cancer imaging. This study represents the first step on a path toward the design of estrogen-based Tc-labeled tracers with improved targeting and SPECT imaging characteristics.
UNLABELLED: Breast and endometrial cancers are the most common invasive malignancies in women, with more than 217,000 new diagnoses per year in the United States. These cancers are often classified into 2 subtypes based on the expression of the classical estrogen receptor. In this study, we describe a new structural class of neutral tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivatives for potential use in breast and endometrial cancer imaging. METHODS: The 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative was synthesized via the Sonogashira cross-coupling reaction and radiolabeled via the tricarbonyl approach. Radiochemical purity was assessed by high-performance liquid chromatography. Cell-binding studies were performed with human breast adenocarcinoma MCF-7 cells. The in vivo biodistribution of the 99mTc(I) derivative was evaluated in virgin female C57BL/6 mice in defined phases of the estrous cycle. Biodistribution and SPECT/CT studies were performed with mice bearing MCF-7 and primary humanendometrial tumors. RESULTS: Radiochemical analysis demonstrated that the postpurification purity of the 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative was > or =95%, with a specific activity of 99mTc of 47.5 TBq/mmol. Cell-binding studies yielded a dissociation constant (mean +/- SEM) of 11 +/- 1.5 nM. In vivo studies revealed that receptor-mediated uptake was present in all phases of the estrous cycle in reproductive organs and mammary glands but was highest during the diestrous phase of the estrous cycle. Despite high nonspecific uptake in the liver, significant receptor-mediated uptake was observed in target tissues and estrogen receptor-expressing tumors (0.67% for MCF-7 tumors and 0.77% for endometrial tumors). Tumor uptake was reduced by approximately 50% on coinjection with 17beta-estradiol. CONCLUSION: We have characterized a novel neutral tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for potential use in breast and endometrial cancer imaging. This study represents the first step on a path toward the design of estrogen-based Tc-labeled tracers with improved targeting and SPECT imaging characteristics.
Authors: Richard R Love; Nguyen Ba Duc; Nguyen Van Dinh; Tian-Zhen Shen; Thomas C Havighurst; D Craig Allred; David L DeMets Journal: J Natl Cancer Inst Date: 2002-05-01 Impact factor: 13.506
Authors: Chetana M Revankar; Daniel F Cimino; Larry A Sklar; Jeffrey B Arterburn; Eric R Prossnitz Journal: Science Date: 2005-02-10 Impact factor: 47.728
Authors: Chetana M Revankar; Hugh D Mitchell; Angela S Field; Ritwik Burai; Cesear Corona; Chinnasamy Ramesh; Larry A Sklar; Jeffrey B Arterburn; Eric R Prossnitz Journal: ACS Chem Biol Date: 2007-07-27 Impact factor: 5.100
Authors: Chinnasamy Ramesh; Bj Bryant; Tapan Nayak; Chetana M Revankar; Tamara Anderson; Kathryn E Carlson; John A Katzenellenbogen; Larry A Sklar; Jeffrey P Norenberg; Eric R Prossnitz; Jeffrey B Arterburn Journal: J Am Chem Soc Date: 2006-11-15 Impact factor: 15.419
Authors: Tapan K Nayak; Megan K Dennis; Chinnasamy Ramesh; Ritwik Burai; Robert W Atcher; Larry A Sklar; Jeffrey P Norenberg; Helen J Hathaway; Jeffrey B Arterburn; Eric R Prossnitz Journal: ACS Chem Biol Date: 2010-07-16 Impact factor: 5.100
Authors: Tapan K Nayak; Chinnasamy Ramesh; Helen J Hathaway; Jeffrey P Norenberg; Jeffrey B Arterburn; Eric R Prossnitz Journal: Mol Cancer Res Date: 2014-07-16 Impact factor: 5.852
Authors: Sudath Hapuarachchige; Gilbert Montaño; Chinnasamy Ramesh; Delany Rodriguez; Lauren H Henson; Casey C Williams; Samuel Kadavakkollu; Dennis L Johnson; Charles B Shuster; Jeffrey B Arterburn Journal: J Am Chem Soc Date: 2011-04-07 Impact factor: 15.419
Authors: Chinnasamy Ramesh; Tapan K Nayak; Ritwik Burai; Megan K Dennis; Helen J Hathaway; Larry A Sklar; Eric R Prossnitz; Jeffrey B Arterburn Journal: J Med Chem Date: 2010-02-11 Impact factor: 7.446